

Sammy Saab

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8782833/sammy-saab-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231
papers

7,203
citations

49
h-index

76
g-index

246
ext. papers

8,118
ext. citations

4.8
avg, IF

5.98
L-index

#	Paper	IF	Citations
231	Barriers for Liver Transplant in Patients with Alcohol-Related Hepatitis.. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 , 12, 13-19	4.1	0
230	Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	
229	Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	0
228	Rural-Urban Geographical Disparities in Hepatocellular Carcinoma Incidence Among US Adults, 2004-2017. <i>American Journal of Gastroenterology</i> , 2021 , 116, 401-406	0.7	5
227	Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 250-257	3	1
226	A Systematic Approach to Pregnancy-Specific Liver Disorders. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 322-329	0.7	1
225	Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. <i>Lipids in Health and Disease</i> , 2021 , 20, 136	4.4	2
224	AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia. <i>Digestive Diseases and Sciences</i> , 2021 , 67, 67	4	
223	Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. <i>Advances in Therapy</i> , 2021 , 38, 5777-5790	4.1	1
222	Frailty Does Not Impact Caregiver Burden in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3343-3351	4	
221	Disparities in Mortality and Health Care Utilization for 460,851 Hospitalized Patients with Cirrhosis and Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2595-2602	4	2
220	Algorithm to Evaluate Abnormal Liver Function Tests in Liver Transplant Patients-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1110	27.4	
219	Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. <i>Advanced Materials Technologies</i> , 2021 , 6, 2001056	6.8	1
218	Accuracy and Safety of 1,055 Transjugular Liver Biopsies in Postliver Transplant Patients. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00355	4.2	1
217	Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	
216	The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 , 11, 45-81	4.1	5
215	History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00378	4.2	0

214	Cardiovascular and metabolic disease in the liver transplant recipient. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2020 , 46-47, 101683	2.5	4
213	Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 762-769	3.4	8
212	Acute Liver Failure During Pregnancy: Happy to Recover from Hep E. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2515-2517	4	
211	Practical Tips on TIPS: When and When Not to Request It. <i>American Journal of Gastroenterology</i> , 2020 , 115, 797-800	0.7	4
210	Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. <i>Journal of Clinical Gastroenterology</i> , 2020 , 54, 503-511	3	4
209	EUS-guided fine-needle core liver biopsy with a modified one-pass, one-actuation wet suction technique comparing two types of EUS core needles. <i>Endoscopy International Open</i> , 2020 , 8, E938-E943	3	6
208	Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles Skid Row. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3023-3031	4	6
207	Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2483-2491	4	5
206	Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. <i>JAMA Network Open</i> , 2020 , 3, e201997	10.4	32
205	Approaches to Assessing Burden in Caregivers of Patients with Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020 , 8, 127-134	5.2	2
204	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist. <i>Clinics in Liver Disease</i> , 2020 , 24, 755-769	4.6	4
203	Estimating paediatric hepatitis C prevalence in the United States. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1455-1461	3.4	0
202	Casting a Wider NET: An Unusual Cause of Acute Liver Failure in a Pregnant Patient. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3102-3105	4	
201	Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3719-3725	4	0
200	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. <i>Nature Communications</i> , 2020 , 11, 4489	17.4	50
199	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019 , 3, 302-310	3.1	17
198	Clinical evaluation of a hepatitis C antibody rapid immunoassay on self-collected oral fluid specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 95, 149-151	2.9	8
197	Management of Thrombocytopenia in Patients with Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 2757-2768	4	21

196	Patient Satisfaction and Healthcare Utilization Using Telemedicine in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1150-1157	4	34
195	Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. <i>BMC Infectious Diseases</i> , 2019 , 19, 626	4	2
194	Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. <i>Clinics in Liver Disease</i> , 2019 , 23, 589-605	4.6	9
193	Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. <i>Clinics in Liver Disease</i> , 2019 , 23, 607-623	4.6	8
192	Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B. <i>Clinical Transplantation</i> , 2019 , 33, e13740	3.8	5
191	Hepatitis C Screening: Barriers to Linkage to Care. <i>Journal of Clinical and Translational Hepatology</i> , 2019 , 7, 226-231	5.2	5
190	Current Treatment of Thrombocytopenia in Chronic Liver Disease. <i>Gastroenterology and Hepatology</i> , 2019 , 15, 558-560	0.7	
189	Relationship between Telomere Maintenance and Liver Disease. <i>Gut and Liver</i> , 2019 , 13, 11-15	4.8	10
188	New Face of Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1782-1788	4	15
187	Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 309-313	3	12
186	Transjugular Liver Biopsy: Safe Even in Patients With Severe Coagulopathies and Multiple Biopsies. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00063	4.2	12
185	Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1110-1118	4	5
184	Presumed Consent: A Potential Tool for Countries Experiencing an Organ Donation Crisis. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1346-1355	4	15
183	Effect of ombitasvir/paritaprevir/ritonavir±dasabuvir regimen on health-related quality of life for patients with hepatitis C. <i>Liver International</i> , 2018 , 38, 1377-1394	7.9	4
182	EUS-guided fine-needle core liver biopsy sampling using a novel 19-gauge needle with modified 1-pass, 1 actuation wet suction technique. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 469-475	5.2	37
181	Case Report: Patient with Hepatitis C, p-ANCA, and Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA Glomerulonephritis. <i>Case Reports in Nephrology and Dialysis</i> , 2018 , 8, 161-170	1.3	1
180	Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective. <i>Clinical Transplantation</i> , 2018 , 32, e13383	3.8	6
179	Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2829-2839	4	10

178	Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1187-1196	0.7	16
177	Elimination of Hepatitis C in Liver Transplant Recipients. <i>Journal of Clinical and Translational Hepatology</i> , 2018 , 6, 247-250	5.2	4
176	Case Series Review of the Safety and Efficacy of Endoscopic Ultrasound-Guided Splenic Mass Core Biopsy. <i>Clinical Endoscopy</i> , 2018 , 51, 600-601	2.5	3
175	Toward the elimination of hepatitis C in the United States. <i>Hepatology</i> , 2018 , 67, 2449-2459	11.2	26
174	Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. <i>Hepatology</i> , 2018 , 67, 847-857	11.2	43
173	Hepatitis C Virus Prevalence in Egyptian Americans in Southern California. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 55-59	3	1
172	Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA . <i>Digestive Diseases and Sciences</i> , 2018 , 63, 3480-3486	4	3
171	Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. <i>Advances in Therapy</i> , 2018 , 35, 1087-1102	4.1	21
170	Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , 2018 , 16, 419-424	0.8	2
169	Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 360-363	3	7
168	Incidence of abnormal liver biochemical tests in hyperthyroidism. <i>Clinical Endocrinology</i> , 2017 , 86, 755-759	3.4	29
167	Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 789-796	3.4	12
166	Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017 , 66, 46-56	11.2	23
165	Endoscopic Ultrasound Liver Biopsies Accurately Predict the Presence of Fibrosis in Patients With Fatty liver. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1477-1478	6.9	11
164	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2174-2181	4	18
163	Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017 , 21, 595-606	4.6	4
162	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017 , 37, 662-668	7.9	16
161	Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. <i>Liver International</i> , 2017 , 37, 1877-1886	7.9	21

160	Liver Transplantation and Bariatric Surgery: Best Approach. <i>Clinics in Liver Disease</i> , 2017 , 21, 215-230	4.6	15
159	Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx109	1	34
158	Extrahepatic Manifestations of Primary Biliary Cholangitis. <i>Gut and Liver</i> , 2017 , 11, 771-780	4.8	26
157	Nonobese nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2017 , 10, 130-133	2.2	5
156	Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 167-173	3	10
155	Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. <i>Clinical Diabetes</i> , 2017 , 35, 79-83	2.9	7
154	Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 101-108	5.2	8
153	Treating Medicaid patients with hepatitis C: clinical and economic impact. <i>American Journal of Managed Care</i> , 2017 , 23, 107-112	2.1	12
152	Nonalcoholic Fatty Liver Disease in Latinos. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 5-12; quiz e9-10	6.9	61
151	Inpatient Cost Assessment of Transjugular Intrahepatic Portosystemic Shunt in the USA from 2001 to 2012. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2838-2846	4	5
150	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016 , 22, 1356-66	4.5	19
149	The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. <i>BMC Gastroenterology</i> , 2016 , 16, 129	3	11
148	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. <i>Medicine (United States)</i> , 2016 , 95, e5048	1.8	29
147	Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. <i>Journal of Clinical and Translational Hepatology</i> , 2016 , 4, 20-5	5.2	2
146	Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. <i>Journal of Clinical and Translational Hepatology</i> , 2016 , 4, 32-8	5.2	14
145	Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2016 , 4, 76-82	5.2	17
144	Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 23-30	0.7	4
143	Medical Management of Metabolic Complications of Liver Transplant Recipients. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 601-608	0.7	8

142	Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. <i>World Journal of Gastroenterology</i> , 2016 , 22, 5780-9	5.6	17
141	Disease Recurrence After Liver Transplantation: Quality of Life and Cost of Retransplantation 2016 , 245-258		
140	Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma. <i>Experimental and Clinical Transplantation</i> , 2016 , 14, 66-71	0.8	2
139	Innovative Linkage to Care for Patients With Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	1
138	Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 2119-27	4.4	6
137	Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. <i>Gut and Liver</i> , 2016 , 10, 509-19	4.8	38
136	Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. <i>Korean Journal of Radiology</i> , 2016 , 17, 472-88	6.9	30
135	Cultural validation of the post-Liver transplant quality of life (pLTQ) questionnaire for the Brazilian population. <i>Annals of Hepatology</i> , 2016 , 15, 377-85	3.1	1
134	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016 , 63, 1112-9	11.2	56
133	Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. <i>Liver International</i> , 2016 , 36, 986-93	7.9	47
132	Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV. <i>Liver International</i> , 2016 , 36, 515-21	7.9	7
131	Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. <i>Journal of Medical Economics</i> , 2016 , 19, 795-805	2.4	16
130	The Management of Hepatitis B in Liver Transplant Recipients. <i>Clinics in Liver Disease</i> , 2016 , 20, 721-736	4.6	7
129	Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. <i>Advances in Therapy</i> , 2016 , 33, 1316-30	4.1	10
128	Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. <i>Liver International</i> , 2015 , 35, 2442-7	7.9	40
127	Boceprevir in liver transplant recipients. <i>Liver International</i> , 2015 , 35, 192-7	7.9	11
126	Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. <i>Gastroenterology</i> , 2015 , 148, 100-107.e1	13.3	266
125	Coffee as modulator of liver injury: Fact and fiction. <i>Clinical Liver Disease</i> , 2015 , 6, 139-141	2.2	4

124	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015 , 15, 175	3	22
123	The outcomes of adult liver transplants in the United States from 1987 to 2013. <i>Liver International</i> , 2015 , 35, 2036-41	7.9	21
122	The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. <i>Liver International</i> , 2015 , 35, 164-70	7.9	56
121	Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. <i>Clinical Transplantation</i> , 2015 , 29, 813-9	3.8	18
120	HCV infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015 , 29, 920-6	3.8	6
119	Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8140-7	5.6	11
118	Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. <i>International Journal of General Medicine</i> , 2015 , 8, 165-73	2.3	19
117	Management of hepatocellular carcinoma with portal vein thrombosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3462-71	5.6	68
116	Hepatitis C Infection in the Elderly. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3170-80	4	29
115	Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3124-9	4	13
114	Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2835-48	4	9
113	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 544-63	6.1	96
112	Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. <i>Liver International</i> , 2015 , 35, 30-6	7.9	62
111	De novo Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of Clinical and Translational Hepatology</i> , 2015 , 3, 284-7	5.2	15
110	Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 294-346	0.7	4
109	Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8271-83	5.6	28
108	Impact of nutrition and obesity on chronic liver disease. <i>Clinics in Liver Disease</i> , 2014 , 18, 205-18	4.6	9
107	The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 686-94	6.1	55

106	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 518-31	6.1	97
105	Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1576-84; quiz 1575, 1585	0.7	30
104	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 657-75	6.1	52
103	Impact of coffee on liver diseases: a systematic review. <i>Liver International</i> , 2014 , 34, 495-504	7.9	123
102	Effects of Clostridium difficile infection in patients with alcoholic hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1745-52.e2	6.9	22
101	Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results. <i>Clinical and Translational Gastroenterology</i> , 2014 , 5, e61	4.2	66
100	Patients with nodular regenerative hyperplasia should be considered for hepatocellular carcinoma screening. <i>Hepatology Research</i> , 2014 , 44, 689-93	5.1	7
99	Hepatitis C and work impairment: a review of current literature. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 595-9	3	17
98	The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. <i>JAMA Internal Medicine</i> , 2014 , 174, 1407-9	11.5	30
97	The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. <i>JAMA Internal Medicine</i> , 2014 , 174, 204-12	11.5	97
96	Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, e76-84	3	21
95	Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 175-9	0.7	7
94	Surveillance for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 745-747	0.7	
93	Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. <i>Current Hepatitis Reports</i> , 2013 , 12, 13-19		
92	Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. <i>Liver Transplantation</i> , 2013 , 19, 1020-9	4.5	22
91	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013 , 57, 1752-62	11.2	97
90	The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. <i>Annals of Surgery</i> , 2013 , 258, 409-21	7.8	153
89	Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. <i>Clinical Transplantation</i> , 2013 , 27, 829-37	3.8	7

88	Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review. <i>Experimental and Clinical Transplantation</i> , 2012 , 10, 531-43	0.8	19
87	Hematopoietic Abnormalities and Hemostasis 2012 , 405-413		1
86	Treating HCV After Liver Transplantation 2012 , 313-323		
85	Trends in viral hepatitis cost-effectiveness studies. <i>American Journal of Managed Care</i> , 2012 , 18, 790-8	2.1	1
84	Recurrence of non-viral liver disease after orthotopic liver transplantation. <i>Liver International</i> , 2011 , 31, 291-302	7.9	20
83	Hepatitis C virus infection in USA: an estimate of true prevalence. <i>Liver International</i> , 2011 , 31, 1090-1017	7.9	323
82	Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. <i>American Journal of Transplantation</i> , 2011 , 11, 511-7	8.7	66
81	Major challenges limiting liver transplantation in the United States. <i>American Journal of Transplantation</i> , 2011 , 11, 1773-84	8.7	126
80	Economic burden associated with patients diagnosed with hepatitis C. <i>Clinical Therapeutics</i> , 2011 , 33, 1268-80	3.5	38
79	Management of Hepatitis C Antiviral Therapy Adverse Effects. <i>Current Hepatitis Reports</i> , 2011 , 10, 33-40		24
78	Interferon for Hepatitis B: Which Populations Benefit the Most. <i>Current Hepatitis Reports</i> , 2011 , 10, 285-291		
77	Development of a disease-specific questionnaire to measure health-related quality of life in liver transplant recipients. <i>Liver Transplantation</i> , 2011 , 17, 567-79	4.5	20
76	Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors. <i>Liver Transplantation</i> , 2011 , 17, 580-90	4.5	33
75	Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 923-30	6.9	57
74	The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. <i>Liver International</i> , 2010 , 30, 19-30	7.9	21
73	Response to Krag et al.. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1444-1445	0.7	
72	Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. <i>Liver International</i> , 2010 , 30, 948-57	7.9	61
71	Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. <i>Annals of Surgery</i> , 2010 , 252, 652-61	7.8	189

70	Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. <i>Current Hepatitis Reports</i> , 2010 , 9, 147-154		7
69	Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. <i>Liver Transplantation</i> , 2010 , 16, 300-7	4.5	104
68	Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. <i>Liver Transplantation</i> , 2010 , 16, 748-59	4.5	38
67	Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. <i>Experimental and Clinical Transplantation</i> , 2010 , 8, 307-13	0.8	23
66	Viral hepatitis in incarcerated adults: a medical and public health concern. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1024-31	0.7	39
65	Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. <i>American Journal of Gastroenterology</i> , 2009 , 104, 993-1001; quiz 1002	0.7	74
64	Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. <i>American Journal of Transplantation</i> , 2009 , 9, 2851-4	8.7	48
63	Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. <i>Liver Transplantation</i> , 2009 , 15, 1525-34	4.5	69
62	Health-related quality of life after liver transplantation for adult recipients. <i>Liver Transplantation</i> , 2009 , 15 Suppl 2, S42-9	4.5	48
61	Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations. <i>Current Hepatitis Reports</i> , 2009 , 8, 43-51		2
60	IUD in transplant recipients. <i>Liver International</i> , 2009 , 29, 475-476	7.9	
59	Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. <i>Liver Transplantation</i> , 2009 , 15, 413-20	4.5	25
58	Health-related quality of life predicts mortality in patients with advanced chronic liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 793-9	6.9	93
57	Pretransplant variables associated with quality of life in liver transplant recipients. <i>Liver International</i> , 2008 , 28, 1087-94	7.9	6
56	Prospective validation of the short form liver disease quality of life instrument. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1088-101	6.1	31
55	Update on management of hepatitis B before and after liver transplantation. <i>Current Hepatitis Reports</i> , 2008 , 7, 25-32		
54	Complications of cirrhosis. <i>Disease-a-Month</i> , 2008 , 54, 445-56	4.4	23
53	Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. <i>Liver International</i> , 2008 , 28, 28-38	7.9	52

52	Pregnancy and cirrhosis. <i>Liver Transplantation</i> , 2008 , 14, 1081-91	4.5	133
51	Treating hepatitis C in the prison population is cost-saving. <i>Hepatology</i> , 2008 , 48, 1387-95	11.2	50
50	Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. <i>Hepatology</i> , 2007 , 46, 1049-56	11.2	47
49	Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. <i>Liver Transplantation</i> , 2007 , 13, 1032-8	4.5	35
48	Employment and quality of life in liver transplant recipients. <i>Liver Transplantation</i> , 2007 , 13, 1330-8	4.5	62
47	Outcomes of liver transplantation using Hepatitis B core-positive liver grafts: Implications for prophylaxis. <i>Current Hepatitis Reports</i> , 2006 , 5, 33-39		
46	Liver and intestine transplantation in the United States, 1995-2004. <i>American Journal of Transplantation</i> , 2006 , 6, 1170-87	8.7	75
45	Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. <i>American Journal of Transplantation</i> , 2006 , 6, 1890-5	8.7	55
44	TIPS versus paracentesis for cirrhotic patients with refractory ascites. <i>The Cochrane Library</i> , 2006 , CD004389	4.8	64
43	Management of patients with cirrhosis in Southern California: results of a practitioner survey. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 156-61	3	25
42	The MELD score in advanced liver disease: association with clinical portal hypertension and mortality. <i>Experimental and Clinical Transplantation</i> , 2006 , 4, 395-9		4
41	Lymphedema tarda after liver transplantation: a case report and review of the literature. <i>Experimental and Clinical Transplantation</i> , 2006 , 4, 567-70		1
40	Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient. <i>Journal of Hepatology</i> , 2005 , 42, 148-9	13.4	8
39	Treatment of hepatitis C. <i>American Journal of Medicine</i> , 2005 , 118, 808-15	2.4	70
38	Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. <i>Annals of Surgery</i> , 2005 , 241, 905-16; discussion 916-8	7.8	312
37	Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. <i>Liver International</i> , 2005 , 25, 940-5	7.9	18
36	Seroepidemiology of hepatitis A in patients with chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 101-5	3.4	17
35	MELD fails to measure quality of life in liver transplant candidates. <i>Liver Transplantation</i> , 2005 , 11, 218-23.5	2.5	96

34	Same day outpatient transjugular liver biopsies in haemophilia. <i>Haemophilia</i> , 2004 , 10, 727-31	3.3	20
33	Liver transplantation in the era of model for end-stage liver disease. <i>Liver International</i> , 2004 , 24, 1-8	7.9	31
32	Outcomes of acute rejection after interferon therapy in liver transplant recipients. <i>Liver Transplantation</i> , 2004 , 10, 859-67	4.5	91
31	TIPS versus paracentesis for cirrhotic patients with refractory ascites. <i>Cochrane Database of Systematic Reviews</i> , 2004 , CD004889		27
30	Primary prevention of cirrhosis. Public health strategies that can make a difference. <i>Postgraduate Medicine</i> , 2004 , 115, 25-30	3.7	13
29	Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. <i>American Journal of Gastroenterology</i> , 2003 , 98, 763-70	0.7	53
28	. <i>Annals of Surgery</i> , 2003 , 237, 666-676	7.8	13
27	Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options. <i>Journal of Clinical Gastroenterology</i> , 2003 , 37, 155-63	3	17
26	Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. <i>Annals of Surgery</i> , 2003 , 237, 666-75; discussion 675-6	7.8	139
25	Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. <i>Liver Transplantation</i> , 2003 , 9, 182-7	4.5	62
24	MELD score predicts 1-year patient survival post-orthotopic liver transplantation. <i>Liver Transplantation</i> , 2003 , 9, 473-6	4.5	164
23	Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. <i>Liver Transplantation</i> , 2003 , 9, 1053-61	4.5	54
22	Fulminant Hepatic Failure. <i>Current Treatment Options in Gastroenterology</i> , 2003 , 6, 473-479	2.5	1
21	Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. <i>American Journal of Transplantation</i> , 2003 , 3, 328-33	8.7	15
20	Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. <i>American Journal of Transplantation</i> , 2003 , 3, 1167-72	8.7	66
19	Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. <i>Liver Transplantation</i> , 2003 , 9, 672-81	4.5	57
18	Practical management of liver transplant recipients for hepatitis C. <i>Minerva Chirurgica</i> , 2003 , 58, 479-89	0.8	1
17	Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin-1. <i>Journal of Biomedical Science</i> , 2002 , 9, 607-612	13.3	18

16	Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?. <i>Liver Transplantation</i> , 2002 , 8, 449-57	4.5	28
15	New era of liver transplantation for hepatitis B: a 17-year single-center experience. <i>Annals of Surgery</i> , 2002 , 235, 611-9; discussion 619-20	7.8	87
14	Pretransplant model to predict posttransplant survival in liver transplant patients. <i>Annals of Surgery</i> , 2002 , 236, 315-22; discussion 322-3	7.8	131
13	Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients. <i>Vaccine</i> , 2002 , 20, 3230-5	4.1	11
12	Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin-1. <i>Journal of Biomedical Science</i> , 2002 , 9, 607-12	13.3	7
11	Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. <i>American Journal of Kidney Diseases</i> , 2001 , 37, 308-15	7.4	58
10	A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. <i>Annals of Surgery</i> , 2001 , 234, 384-93; discussion 393-4	7.8	207
9	Tests for acute and chronic viral hepatitis. Finding your way through the alphabet soup of infection and superinfection. <i>Postgraduate Medicine</i> , 2000 , 107, 123-6, 129-30	3.7	10
8	Tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin does not require extracellular signal-regulated kinase activation in Swiss 3T3 cells stimulated by bombesin or platelet-derived growth factor. <i>Journal of Cellular Physiology</i> , 2000 , 183, 208-20	7	15
7	A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination. <i>American Journal of Medicine</i> , 2000 , 109, 241-4	2.4	23
6	Liver transplantation. Selection, listing criteria, and preoperative management. <i>Clinics in Liver Disease</i> , 2000 , 4, 513-32	4.6	9
5	Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. <i>Gastroenterology</i> , 2000 , 119, 1382-4	13.3	53
4	Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. <i>Journal of Rheumatology</i> , 1998 , 25, 801-6	4.1	46
3	Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 1981-5	4	31
2	Evolving misidentification syndromes and facial recognition deficits. <i>Canadian Journal of Psychiatry</i> , 1992 , 37, 574-6	4.8	5
1	Approach to the Patient with Chronic Viral Hepatitis B or C516-525		